Autologous platelet lysate product versus placebo in patients with chronic leg ulcerations: A pilot study using a randomized, double-blind, placebo-controlled trial

Brent Weed, Mark D P Davis, Cindy L. Felty, David A. Liedl, Alvaro A. Pineda, S. Breanndan Moore, Thom W Rooke

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The objective of the authors' study was to assess the ability of autologous platelet lysate factors to facilitate healing of chronic cutaneous ulcers. Twenty-six patients with chronic leg ulcers participated in this prospective, randomized, double-blind, placebo-controlled trial at the wound care center at a tertiary care institution. Fifteen patients received autologous platelet lysate product mixed with collagen (treatment group); 11 patients received platelet-poor plasma mixed with collagen (placebo group). Treatment was applied twice daily for 12 weeks. After a two-week washout period, patients whose ulcers had not healed were assigned to receive the other treatment for an additional 12 weeks. The principal end point was the occurrence of complete healing (100% epithelialization of the entire target ulcer) as assessed by ulcer photography and clinical examination. A secondary end point was the rate at which the wound healed. Demographic characteristics were similar in both groups. There was no significant difference between the treatment group and the placebo group as measured by area of the wounds and by the randomization strategy at baseline, Week 12 (end of the first treatment period), and Week 28 (end of the study period). The rate of healing was not significantly different between the treatment group and the placebo group. The median slope estimating the rate of healing over time was -0.79 for the treatment group and -0.84 for the placebo group. The addition of autologous platelet lysate product to collagen did not accelerate the rate of wound healing or significantly decrease wound size compared with platelet-poor plasma with collagen.

Original languageEnglish (US)
Pages (from-to)273-282
Number of pages10
JournalWounds
Volume16
Issue number9
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Leg
Blood Platelets
Placebos
Collagen
Ulcer
Wounds and Injuries
Therapeutics
Skin Ulcer
Leg Ulcer
Photography
Tertiary Healthcare
Random Allocation
Wound Healing
Demography

ASJC Scopus subject areas

  • Surgery

Cite this

Autologous platelet lysate product versus placebo in patients with chronic leg ulcerations : A pilot study using a randomized, double-blind, placebo-controlled trial. / Weed, Brent; Davis, Mark D P; Felty, Cindy L.; Liedl, David A.; Pineda, Alvaro A.; Moore, S. Breanndan; Rooke, Thom W.

In: Wounds, Vol. 16, No. 9, 09.2004, p. 273-282.

Research output: Contribution to journalArticle

Weed, Brent ; Davis, Mark D P ; Felty, Cindy L. ; Liedl, David A. ; Pineda, Alvaro A. ; Moore, S. Breanndan ; Rooke, Thom W. / Autologous platelet lysate product versus placebo in patients with chronic leg ulcerations : A pilot study using a randomized, double-blind, placebo-controlled trial. In: Wounds. 2004 ; Vol. 16, No. 9. pp. 273-282.
@article{44cff910afd44eb391a1621f1c2deaf9,
title = "Autologous platelet lysate product versus placebo in patients with chronic leg ulcerations: A pilot study using a randomized, double-blind, placebo-controlled trial",
abstract = "The objective of the authors' study was to assess the ability of autologous platelet lysate factors to facilitate healing of chronic cutaneous ulcers. Twenty-six patients with chronic leg ulcers participated in this prospective, randomized, double-blind, placebo-controlled trial at the wound care center at a tertiary care institution. Fifteen patients received autologous platelet lysate product mixed with collagen (treatment group); 11 patients received platelet-poor plasma mixed with collagen (placebo group). Treatment was applied twice daily for 12 weeks. After a two-week washout period, patients whose ulcers had not healed were assigned to receive the other treatment for an additional 12 weeks. The principal end point was the occurrence of complete healing (100{\%} epithelialization of the entire target ulcer) as assessed by ulcer photography and clinical examination. A secondary end point was the rate at which the wound healed. Demographic characteristics were similar in both groups. There was no significant difference between the treatment group and the placebo group as measured by area of the wounds and by the randomization strategy at baseline, Week 12 (end of the first treatment period), and Week 28 (end of the study period). The rate of healing was not significantly different between the treatment group and the placebo group. The median slope estimating the rate of healing over time was -0.79 for the treatment group and -0.84 for the placebo group. The addition of autologous platelet lysate product to collagen did not accelerate the rate of wound healing or significantly decrease wound size compared with platelet-poor plasma with collagen.",
author = "Brent Weed and Davis, {Mark D P} and Felty, {Cindy L.} and Liedl, {David A.} and Pineda, {Alvaro A.} and Moore, {S. Breanndan} and Rooke, {Thom W}",
year = "2004",
month = "9",
language = "English (US)",
volume = "16",
pages = "273--282",
journal = "Wounds",
issn = "1044-7946",
publisher = "HMP Communications",
number = "9",

}

TY - JOUR

T1 - Autologous platelet lysate product versus placebo in patients with chronic leg ulcerations

T2 - A pilot study using a randomized, double-blind, placebo-controlled trial

AU - Weed, Brent

AU - Davis, Mark D P

AU - Felty, Cindy L.

AU - Liedl, David A.

AU - Pineda, Alvaro A.

AU - Moore, S. Breanndan

AU - Rooke, Thom W

PY - 2004/9

Y1 - 2004/9

N2 - The objective of the authors' study was to assess the ability of autologous platelet lysate factors to facilitate healing of chronic cutaneous ulcers. Twenty-six patients with chronic leg ulcers participated in this prospective, randomized, double-blind, placebo-controlled trial at the wound care center at a tertiary care institution. Fifteen patients received autologous platelet lysate product mixed with collagen (treatment group); 11 patients received platelet-poor plasma mixed with collagen (placebo group). Treatment was applied twice daily for 12 weeks. After a two-week washout period, patients whose ulcers had not healed were assigned to receive the other treatment for an additional 12 weeks. The principal end point was the occurrence of complete healing (100% epithelialization of the entire target ulcer) as assessed by ulcer photography and clinical examination. A secondary end point was the rate at which the wound healed. Demographic characteristics were similar in both groups. There was no significant difference between the treatment group and the placebo group as measured by area of the wounds and by the randomization strategy at baseline, Week 12 (end of the first treatment period), and Week 28 (end of the study period). The rate of healing was not significantly different between the treatment group and the placebo group. The median slope estimating the rate of healing over time was -0.79 for the treatment group and -0.84 for the placebo group. The addition of autologous platelet lysate product to collagen did not accelerate the rate of wound healing or significantly decrease wound size compared with platelet-poor plasma with collagen.

AB - The objective of the authors' study was to assess the ability of autologous platelet lysate factors to facilitate healing of chronic cutaneous ulcers. Twenty-six patients with chronic leg ulcers participated in this prospective, randomized, double-blind, placebo-controlled trial at the wound care center at a tertiary care institution. Fifteen patients received autologous platelet lysate product mixed with collagen (treatment group); 11 patients received platelet-poor plasma mixed with collagen (placebo group). Treatment was applied twice daily for 12 weeks. After a two-week washout period, patients whose ulcers had not healed were assigned to receive the other treatment for an additional 12 weeks. The principal end point was the occurrence of complete healing (100% epithelialization of the entire target ulcer) as assessed by ulcer photography and clinical examination. A secondary end point was the rate at which the wound healed. Demographic characteristics were similar in both groups. There was no significant difference between the treatment group and the placebo group as measured by area of the wounds and by the randomization strategy at baseline, Week 12 (end of the first treatment period), and Week 28 (end of the study period). The rate of healing was not significantly different between the treatment group and the placebo group. The median slope estimating the rate of healing over time was -0.79 for the treatment group and -0.84 for the placebo group. The addition of autologous platelet lysate product to collagen did not accelerate the rate of wound healing or significantly decrease wound size compared with platelet-poor plasma with collagen.

UR - http://www.scopus.com/inward/record.url?scp=7044233262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044233262&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:7044233262

VL - 16

SP - 273

EP - 282

JO - Wounds

JF - Wounds

SN - 1044-7946

IS - 9

ER -